Irinotecan liposome、5-fluorouracil、Leucovorin

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Advanced Solid TumorsSecond-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

Phase 1

A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors

CompletedNCT05086848

Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors

Start: 2016-05-05End: 2018-06-06Updated: 2021-10-21

Phase 3

Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer

CompletedNCT05074589

Jiangsu HengRui Medicine Co., Ltd.Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

Start: 2018-01-25End: 2022-03-10Updated: 2023-08-14

Related Papers

Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China

PLoS ONE2026-06-22

Cost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma.

2025-11-12

Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.

2024-09-1911 citations

Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.

2024-07-221 citations